Mereo BioPharma Group, a United Kingdom-based clinical-stage biopharmaceutical firm, has agreed to merge with OncoMed Pharmaceuticals, an oncology-focused clinical stage biopharmaceutical business, it was reported yesterday.
The deal has been unanimously approved by the board of directors of each company. Subject to potential adjustment as described below, based upon an OncoMed net cash balance of USD38m at completion, current Mereo shareholders are expected to own around 75% of the issued share capital of the Enlarged Group, while current OncoMed shareholders are expected to own approximately 25% of the issued share capital of the Enlarged Group (through their holding of ADRs). In addition, OncoMed shareholders will receive CVRs representing the right to receive future conditional cash payments and additional ADRs based on the achievement of certain milestones relating to OncoMed assets.
Based on the terms of an agreement and plan of merger and reorganisation, unanimously approved by each party's board of directors, each share of OncoMed issued and held immediately prior to the deal becoming effective will be converted into the right to receive, Mereo ADRs pursuant to an exchange ratio that has been agreed, and one CVR representing the contingent right to receive certain cash payments and Mereo ADRs upon the achievement of certain milestones relating to the drugs etigilimab and navicixizumab.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval